This Peptide Changes Everything
- Appetite Suppression
- Superior Weight Reduction
- Metabolic Improvement
- Fulfilled In USA
the next generation of metabolic Health
28%
Average body weight reduction. The highest ever recorded in a late-stage obesity trial
71 lbs
Average weight lost by users. More than any weight loss drug ever studied.
93%
Achieved normal liver fat levels at 48 weeks. Fatty liver disease reversed.
3x
Hormonal pathways targeted simultaneously: GLP-1, GIP, and Glucagon receptors
Excess weight is widely recognized by medical bodies as a chronic condition with a strong biological and hormonal component. Retatrutide works by supporting the correction of hormonal signals involved in appetite regulation, energy expenditure, and glucose control, as demonstrated in published clinical research.
clinical applications
Published clinical research on retatrutide spans multiple metabolic health areas.
Obesity & Weight Management
Blood Sugar & Glycemic Health
Liver Fat & Metabolic Health
Diabetic Kidney Disease
The most studied weight management compound ever
Retatrutide
Formula: C₂₂₁H₃₄₂N₄₆O₆₈
- Over 99% Purity verified by independent third-party HPLC/UV/MS
- Third-party lab tested
- Lyophilized peptide format (research vials)
- Mannitol-free (no bulking agents or buffers)
- Certificate of Analysis
- FULFILLED IN USA
Specifications
Product Name: GLP-3 Quantity: 10/20/30mg (Lyophilized Powder) CAS #: Molecular Formula: C₂₂₃H₃₄₃F₃N₄₆O₇₀ Confirmed Molecular Weight (MS): 4728.48 Da Purity (HPLC): 99.6% Method of Analysis: HPLC-UV-MS
Purity Testing
High Performance Liquid Chromatography (HPLC-UV) testing confirms:
• Purity: 99.6%
• Minimal secondary peak detection
• Lot-specific Certificate of Analysis available
Terms of Sale
By completing your purchase, you confirm that you are a qualified professional conducting lawful scientific research. You agree that this compound is for research use only—not for human consumption or any non-research purpose. Reta 100 accepts no responsibility for misuse, mishandling, or improper application of this material.
Strictly for laboratory research, analytical testing, and scientific investigation. Research use only. Not for human consumption, therapeutic, or diagnostic use.
Targeting 3 Hormonal Pathways with 1 Peptide
Think of your metabolism like a lock with three keys. Most weight loss drugs only carry one. Retatrutide carries all three. Retatrutide simultaneously engages GLP-1, GIP, and glucagon receptors. The first in the world.
01
GLP-1 Receptor Activation
The mechanism includes stimulating insulin release, reducing glucagon secretion, suppressing appetite, and prolonging gastric emptying. GLP-1 receptors are expressed in multiple tissues—including the pancreas, brain, heart, kidneys, and gut—resulting in a broad spectrum of metabolic effects.
Suppresses brain hunger signals
Stabilizes blood sugar
Slow digestion keeps you full longer
02
GLP-1 Receptor Activation
This compound works synergistically with GLP-1 to boost insulin secretion and curb appetite. Additionally, GIP receptor activation affects bone metabolism and adipose tissue, reducing fat storage and supporting healthier lipid processing.
Amplify the body’s insulin response
Enhances how efficiently fat is stored and released
Deepens appettite-supressing effect of GLP-1
03
Glucagon Receptor Activation
Promotes energy expenditure, reduces lipogenesis, induces lipolysis, and reduces GI motility. Glucagon receptor action drives fat burning from the liver and adipose tissue, directly amplifying weight loss beyond what GLP-1 alone achieves.
Drives the liver to burn stored fat for fuel
Raises your metabolic rate
Keeps fat loss active between meals
unmatched in all metrics
METRIC
OZEMPIC
MOUNJARO
RETATRUTIDE
Receptors Targeted
1 (GLP-1)
2 (GLP-1, GIP)
3 (GLP-1, GIP, Glucagon)
Avg. Weight Loss (Max Dose)
15% (68 weeks)
22.5% (72 weeks)
28.7% (68 weeks, Phase 3)
Average Pounds Lost
34 lbs
48 lbs
71 lbs (Phase 3)
Fat Burning (Metabolism)
Appetite Only
Appetite + Insulin
Appetite + Insulin + Direct Fat Burn
Liver Fat Reduction
Moderate
Significant
93% Achieve Normal Liver Fat
Dosing Frequency
Once Weekly
Once Weekly
Once Weekly
Comparison data is drawn from the following published clinical trials: semaglutide (STEP-1), tirzepatide (SURMOUNT-1), and retatrutide (TRIUMPH-4, Phase 3, December 2025). Because these trials were conducted independently by different companies in distinct patient populations, the figures are not directly comparable without appropriate adjustment. Notably, individual outcomes varied considerably in all three studies.
Join Our Newsletter
Receive free advice, daily updates and specials directly to your inbox!
- No Spam, Only Genuine Updates
IMPORTANT LEGAL & MEDICAL DISCLAIMER — PLEASE READ
Retatrutide is an investigational compound not approved by the U.S. Food and Drug Administration (FDA) for the treatment, cure, or prevention of any disease or condition, including obesity or Type 2 diabetes.
All products listed are for research and development purposes only and are strictly not for human consumption. Reta 100 is a wholesale chemical supplier—not a compounding pharmacy, compounding facility (as defined under 503A), or outsourcing facility (as defined under 503B). The statements on this website have not been evaluated by the FDA, and our products are not intended to diagnose, treat, cure, or prevent any disease.
Information provided is based on clinical trial data and is for educational reference only.